NCT05101070 2026-03-18
aCCeleR8-001
Shionogi Inc.
Phase 1/2 Recruiting
Clinical Trials
27 trialsNCT06885281 2026-02-13
A Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1/2 Recruiting
NCT03917381 2026-02-11
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT07265622 2025-12-29
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT07105215 2025-11-26
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT07055594 2025-11-06
NbTAST-01
Shine-On Biomedical Co., Ltd.
Phase 1/2 Recruiting
NCT06873789 2025-10-15
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Active not recruiting
NCT07158918 2025-09-08
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
Phase 1/2 Recruiting
NCT04685226 2025-09-02
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Recruiting
NCT06992687 2025-05-28
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Enrolling by invitation
NCT06947226 2025-04-27
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06928363 2025-04-15
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT02240238 2025-01-22
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NanoCarrier Co., Ltd.
Phase 1/2 Completed
NCT06764628 2025-01-22
A Study of SHR-4375 in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT05416749 2024-11-20
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Suspended
NCT04174716 2024-09-27
VASTUS
Idience Co., Ltd.
Phase 1/2 Completed
NCT01283945 2024-07-25
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Servier
Phase 1/2 Completed
NCT06233292 2024-06-14
A Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT02598960 2023-03-06
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05740215 2023-02-22
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
Shandong New Time Pharmaceutical Co., LTD
Phase 1/2 Unknown
NCT02593786 2022-10-24
CheckMate 077
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03965845 2022-09-19
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Completed
NCT02639546 2022-09-16
iMATRIXcobi
Hoffmann-La Roche
Phase 1/2 Completed
NCT05524194 2022-09-01
6MW3511 in Patients With Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05216965 2022-06-15
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT02587962 2021-01-14
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
Phase 1/2 Terminated
NCT03035591 2019-10-15
BETIDES
Orion Corporation, Orion Pharma
Phase 1/2 Completed